Aktieanalys

Nanexa: NEX-20 Ph 1 study completed - ABG

ABG Sundal Collier Publicerad: 06 Oct 2023 09:14

NEX-20 Ph 1 study in multiple myeloma completed
Mild to moderate local skin reactions; new formulation under development
Investor meeting next Monday 9 Oct at Uppsala premises

Nanexa finishes Ph 1 study with NEX-20 in multiple myeloma

Nanexa has announced the completion of the Ph 1 clinical trial of NEX-20 in multiple myeloma, with the last follow-up visit for the highest dosage level now concluded. The safety profile of NEX-20 did not reveal any unexpected adverse events that could compromise the use of lenalidomide together with PharmaShell, aside from the localized dose-dependent skin reactions (ranging from mild to moderate) at the injection site, as previously reported in August. All skin reactions subsided during the study period.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/nanexa/Equity-research/2023/10/nanexa---nex-20-ph-1-study-completed-/

Nyheter om Nanexa

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!